<DOC>
	<DOCNO>NCT02162472</DOCNO>
	<brief_summary>The aim study determine videocapillaroscopy could use objective reliable method ass psoriasis severity document improvement treatment measure change vascular feature .</brief_summary>
	<brief_title>Videocapillaroscopy Assessment During Systemic Agent Therapy Psoriasis</brief_title>
	<detailed_description>This single-center , prospective , observational study recruit subject Northwestern University examine degree improvement psoriatic plaque systemic therapy treatment . Thirty patient confirm diagnosis `` active '' psoriasis treat single systemic agent recruit Northwestern Medical Faculty Foundation Dermatology clinic . The study population include 15 patient receive adalimumab 15 patient receive methotrexate . Eight visit complete subject : visit 0 ( baseline ) visit 1-8 ( week 2 , 4 , 6 , 8 , 12 , 16 24 ) . At baseline visit , informed consent obtain , capillaroscopic examination perform assess evidence characteristic vascular alteration . If change present , remainder baseline visit complete . This include gather personal information ( age , race , gender etc . ) , clinical history ( time first diagnosis , presentation site , treatment use , biopsy result previously perform , etc . ) past medical history ( include current previous medication ) . At subsequent visit ( visit 1-8 ) , change medical history and/or medication obtain record . At eight visit , dermatologic physical examination , include PASI PGA score perform .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Subjects clinical diagnosis chronic active plaque psoriasis Subjects eligible systemic monotherapy ( oral biologic agent ) . Subjects evidence characteristic vascular alteration capillaroscopic examination . Subjects able complete study visit procedure , include completion DLQI questionnaire . Subjects willing standardized digital photograph take 2 different target plaque lesion extremity . Subjects willing videocapillaroscopic photograph take 2 different target plaque lesion well 2 area uninvolved skin extremity . Subjects `` 4 week '' washout period recently change systemic psoriatic therapy . Those fit inclusion criterion . Subjects unable understand protocol give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>videocapillaroscopy , psoriasis , systemic agent</keyword>
</DOC>